Source: Investing.com ↗

AbbVie reports positive phase 3 trial for menstrual migraine drug

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

USDC/USDT

$1.00

-0.01%

BTC/USDT

$86,207.29

+0.94%

ETH/USDT

$2,744.97

+0.62%

ZEC/USDT

$1,626.07

+7.28%

XRP/USDT

$1.62

+6.56%